<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561457</url>
  </required_header>
  <id_info>
    <org_study_id>BPV-1021</org_study_id>
    <nct_id>NCT00561457</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System</brief_title>
  <acronym>Luminexx</acronym>
  <official_title>A Clinical Evaluation of the Bard® Luminexx™ Iliac Stent and Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and effectiveness of the LUMINEXX stent for the proposed indication
      of treatment of common and/or external iliac artery occlusive disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to collect safety and efficacy data on the Bard Luminexx Iliac Stent in
      a broad patient population having indications for iliac stenting. Effectiveness in this study
      will be demonstrated by the prevention of Major Adverse Clinical Events (MACE). The composite
      primary endpoint of this clinical trial is freedom from peri-procedural death and freedom
      from stented segment revascularization or restenosis (&gt;50%) at nine months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Major Adverse Clinical Events (MACE)</measure>
    <time_frame>9-months</time_frame>
    <description>Major Adverse Clinical Events defined as peri-procedural death (death during the procedure or prior to hospital discharge), target lesion revascularization (TLR), or stented segment restenosis (&gt; 50%) at nine months postprocedure.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Iliac Artery Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>Iliac Stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stent placement in the iliac artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bard Luminexx Iliac Stent and Delivery System</intervention_name>
    <description>Iliac Stenting</description>
    <arm_group_label>Iliac Stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient or legal guardian understands procedure and provides written informed consent
             prior to study participation.

          -  Patient must be able and willing to comply with all study procedures including
             scheduled follow-up visits and diagnostic tests.

          -  Lesion(s) distinctly localized in the common and/or external iliac arteries.

          -  Reference lumen diameter (RLD) 6 mm and 9 mm.

          -  Stenosis 30% and symptomatic ischemic disease (Category 1-6 Chronic Limb Ischemia or
             Threatened or Irreversible Acute Limb Ischemia).

        Exclusion Criteria:

          -  Patients diagnosed with preoperative coagulation disorder or with contraindications to
             antiplatelet or anticoagulant therapy.

          -  Patients who are pregnant or planning to become pregnant during the clinical
             investigation.

          -  Patients with a life expectancy &lt; 3 years.

          -  Patients currently or scheduled to be enrolled in another investigation that conflicts
             with follow-up testing or may confound the study data.

          -  Patients with absolute contraindication to x-ray contrast media or medications
             normally administered during an interventional procedure.

          -  Patients with severe tortuosity or angulation of a vessel that may prevent access in
             the opinion of the investigator.

          -  The presence of soft, thrombotic or embolic material within or adjacent to the
             lesion(s) being treated with the study device, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <results_first_submitted>May 26, 2009</results_first_submitted>
  <results_first_submitted_qc>April 6, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2011</results_first_posted>
  <last_update_submitted>January 17, 2017</last_update_submitted>
  <last_update_submitted_qc>January 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iliac</keyword>
  <keyword>Artery</keyword>
  <keyword>Occlusive</keyword>
  <keyword>Stenosis</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject enrollment was completed November 1, 2004 with a total of 134 patients from 9 study sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Luminexx Iliac Stent and Delivery System</title>
          <description>Bard® LUMINEXX* Iliac Stent and the Bard® LUMINEXX* 6F Iliac Stent systems.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Luminexx Iliac Stent and Delivery System</title>
          <description>Bard® LUMINEXX* Iliac Stent and the Bard® LUMINEXX* 6F Iliac Stent systems.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.31" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Major Adverse Clinical Events (MACE)</title>
        <description>Major Adverse Clinical Events defined as peri-procedural death (death during the procedure or prior to hospital discharge), target lesion revascularization (TLR), or stented segment restenosis (&gt; 50%) at nine months postprocedure.</description>
        <time_frame>9-months</time_frame>
        <population>The analysis was an intention to treat (ITT)population which included the data for all completed patients (those who had a MACE event within 9-months and those who reached 9 months without experiencing an event). Natural censoring was used in the analysis according to the statistical analysis plan.</population>
        <group_list>
          <group group_id="O1">
            <title>Luminexx Iliac Stent and Delivery System</title>
            <description>Bard® LUMINEXX* Iliac Stent and the Bard® LUMINEXX* 6F Iliac Stent systems.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Major Adverse Clinical Events (MACE)</title>
          <description>Major Adverse Clinical Events defined as peri-procedural death (death during the procedure or prior to hospital discharge), target lesion revascularization (TLR), or stented segment restenosis (&gt; 50%) at nine months postprocedure.</description>
          <population>The analysis was an intention to treat (ITT)population which included the data for all completed patients (those who had a MACE event within 9-months and those who reached 9 months without experiencing an event). Natural censoring was used in the analysis according to the statistical analysis plan.</population>
          <units>MACE events per 9 months</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.153" lower_limit="0.0905" upper_limit="0.2292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Luminexx Iliac Stent and Delivery System</title>
          <description>Bard® LUMINEXX* Iliac Stent and the Bard® LUMINEXX* 6F Iliac Stent systems.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina/Coronary Ischemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Myocardial Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Valvular Heart Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cardiovascular Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (non-sepsis)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Upper Extremity Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>False Aneurysm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Squamous Cell Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Carotid Artery Disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Complications</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Distal Revascularization (Target Limb)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Revascularization (Non-target Limb)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Target Lesion Revascularization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Amputation on Study Side Limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dissection (Target Vessel)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Revascularization Target Limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Claudication (Non-target limb)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Claudication (Target Limb)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Critical Limb Ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Aneurysm (Site Other)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Arterial Perforation/Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina/Coronary Ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Complications</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Affairs</name_or_title>
      <organization>Bard Peripheral Vascular</organization>
      <phone>480-303-2644</phone>
      <email>John.Reviere@crbard.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

